Title: Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
Journal: Current opinion in investigational drugs (London, England : 2000)20101201
Title: A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib.
Journal: PLoS computational biology20101101
Title: KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Journal: Experimental hematology20100901
Title: [Development of ABL tyrosine kinase inhibitors].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20100801
Title: Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Journal: Cancer20100601
Title: A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Journal: Leukemia20100101
Title: Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20090701
Title: Imatinib and its successors--how modern chemistry has changed drug development.
Journal: Current pharmaceutical design20090101
Title: The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
Journal: Cell death and differentiation20081101
Title: Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Journal: Leukemia research20080601
Title: Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Journal: International journal of cancer20080601
Title: Management of patients with resistant or refractory chronic myelogenous leukemia.
Journal: Oncology (Williston Park, N.Y.)20080415
Title: Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Journal: Cell death and differentiation20070901
Title: Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Journal: Cancer science20070801
Title: [Novel anti-CML agents beyond imatinib].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20070601
Title: Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.
Journal: Bioorganic & medicinal chemistry letters20070515
Title: [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy20070201
Title: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Journal: Blood20070101
Title: New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Journal: Seminars in hematology20070101
Title: [Molecular targeting therapy for chronic myeloid leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20070101
Title: NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.
Journal: Analytical chemistry insights20070101
Title: In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
Journal: Leukemia research20061101
Title: Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters20060301
Title: [Novel inhibitors of Bcr-Abl].
Journal: Postepy higieny i medycyny doswiadczalnej (Online)20060101
Title: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.
Journal: Blood20051201
Title: Grace MS, et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol. 2014 Aug;171(16):3881-3894.
Title: Kimura S, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005 Dec 1;106(12):3948-3954.
Title: Kamitsuji Y, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008, 15(11), 1712-2172.
Title: Yokota A, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007, 109(1), 306-314.
Title: Kuroda J, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007;14(9):1667-1677.
